Why Drug Repurposing Programs Fail Mechanism Audits — And What to Do Before Governance Review

The promise of drug repurposing is straightforward: an asset with a known safety profile, applied to a new indication, shortens the path to clinic. The reality is that most repurposing programs that fail do so not because the asset was wrong — but because the mechanism hypothesis connecting it to the new indication was never independently audited.

Internal teams are not positioned to provide this audit. They are built to advance the program, not to stress-test it. Literature reviews surface what is accessible, not what is active and unpublished. Predictive models evaluate outcomes within assumptions — they do not question whether the assumptions hold.

The result is a mechanism claim that has been internally refined but never externally challenged. When governance committees, licensing partners, or regulatory reviewers apply external scrutiny, gaps surface that should have been addressed months earlier.

Independent mechanism defense audits exist to close this gap before it becomes a program-level problem.

A structured audit evaluates six dimensions that internal analysis routinely misses: whether the target is a causal driver of disease biology or a downstream correlation; whether the biological signal reproduces across independent datasets and modalities; whether the target occupies an essential position in the relevant pathway; what contradictions exist in the global research landscape, including from programs that have not yet published; what evidence gaps remain in the mechanistic chain; and what parallel programs are active in the same indication space.

The last two are the most consequential. Evidence gaps are the questions a governance committee will ask. Parallel programs are the competitive pressure that affects portfolio prioritization and licensing leverage. Both are invisible to internal analysis. Both are surfaced through cross-institutional reasoning that no single organization can replicate.

Skygenic delivers this audit as a structured report — scoped per engagement, delivered before the decision point where the mechanism will face external scrutiny. The audit does not generate new data. It evaluates whether the mechanism hypothesis holds under the weight of everything known, active, and pre-publication across thousands of cross-referenced datasets.

For drug repurposing programs approaching governance review, indication expansion decisions, or licensing discussions, the question is not whether an independent mechanism audit is valuable. It is whether the program can afford to proceed without one.

skygenic.com/audits/pharma/drug-repurposing